A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs DSM 265 (Primary)
- Indications Malaria
- Focus Adverse reactions; First in man; Pharmacokinetics
- 06 Aug 2015 Status changed from completed to active, no longer recruiting, as reported by Australian New Zealand Clinical Trials Registry source.
- 06 Aug 2015 Status changed from active, no longer recruiting to completed as per Australian New Zealand Clinical Trials Registry record.
- 27 Nov 2013 New trial record